Utility scores and treatment preferences for clinical early-stage cervical cancer

Value in Health

Volumn 14, Issue 4, 2011, Pages 582-586

  Jewell, Elizabeth L ^a,b,c   Smrtka, Michael ^a   Broadwater, Gloria ^a   Valea, Fidel ^a,b   Davis, Debra M ^a   Nolte, Kimberly C ^a   Valea, Renea ^a   Myers, Evan R ^a,b   Samsa, Gregory ^a   Havrilesky, Laura J ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cervical cancer; Cost analyses; Treatment options; Utility scores

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; EARLY CANCER; FEMALE; HUMAN; PATIENT ATTITUDE; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; SCORING SYSTEM; UTERINE CERVIX CANCER; VISUAL ANALOG SCALE; VOLUNTEER;

EID: 79960006165     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.11.017     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Hopkins MP, Morley GW. Radical hysterectomy versus radiation therapy for stage IB squamous cell cancer of the cervix. Cancer 1991;68:272-7.
3. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-40. (Pubitemid 27348428)
4. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study. Gynecol Oncol 1991;40:55-65.
5. Newton M. Radical hysterectomy or radiotherapy for stage I cervical cancer. A prospective comparison with 5 and 10 years follow-up. Am J Obstet Gynecol 1975;123:535-42.
6. Eifel PJ, Morris M, Wharton JT, Oswald MJ. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994;29:9-16. (Pubitemid 24138859)
7. Havrilesky LJ, Leath CA, Huh W, et al. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecol Oncol 2004;93:429-34. (Pubitemid 38507613)
8. Kamelle SA, Rutledge TL, Tillmanns TD, et al. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol 2004;94:249-55. (Pubitemid 39024524)
9. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61. (Pubitemid 29177874)
10. Peters WA, 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.
11. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53. (Pubitemid 29177873)
12. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol 1999;73:177-83. (Pubitemid 29215728)
13. Whitney CW, Stehman FB. The abandoned radical hysterectomy: a gynecologic oncology group study. Gynecol Oncol 2000;79:350-6.
14. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22:872-80. (Pubitemid 41103599)
15. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48. (Pubitemid 29220838)
16. Grigsby PW. Primary radiotherapy for stage IB or IIA cervical cancer. J Natl Cancer Inst Monogr 1996;21:61-4.
17. Rocconi RP, Estes JM, Leath CA 3rd, et al. Management strategies for stage IB2 cervical cancer: a cost-effectiveness analysis. Gynecol Oncol 2005;97:387-94. (Pubitemid 40614879)
18. Jewell EL, Kulasingam S, Myers E, et al. Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. Gyneco Oncol 2007;107:532-40. (Pubitemid 350160869)
19. Gold MR, Russell L, Weintstein M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
20. Drummond M. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford Medical Publications. 2005.
21. Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999;3(i-iv):1-64.
22. Calhoun EA, Bennett CL, Peeples PA, et al. Perceptions of cisplatin-related toxicities among ovarian cancer patients and gynecologic oncologists. Gynecol Oncol 1998;71:369-75. (Pubitemid 29022321)
23. Lloyd A, Nafees B, Narweska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95:683-90. (Pubitemid 44373482)
24. Ortega A, Dranitsaris G, Sturgeon J, et al. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 1997;66:4454-63.
25. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000;88:1294-303. (Pubitemid 30155164)
26. Stein K, Sugar C, Velikova G, Stark D. Putting the 'Q' in quality adjusted life years (QALYs) for advanced ovarian cancer - an approach using data clustering methods and the internet. Eur J Cancer 2007;43,104-13. (Pubitemid 46054478)
27. Sun CC, Bodurka DC, Donato ML, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 2002;87:118-28. (Pubitemid 36027111)
28. Havrilesky LJ, Broadwater G, Davis DM, et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol 2009;113:216-20.
29. Bruner DW, Hanlon A, Mazzoni S, et al. Predictors or preferences and utilities in men treated with 3D-CRT for prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:34-42. (Pubitemid 38010334)
30. EuroQol - a new a facility for the measurement of health related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
31. Frank SJ, Pisters LL, Davis J, et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 2007;177:2151-6. (Pubitemid 46726403)
32. Shrader-Bogen CL, Kjellberg JL, McPherson CP, et al. Quality of life and treatment outcomes: prostate carcinoma patients' perspective after prostatectomy or radiation therapy. Cancer 1997;79:1977-86. (Pubitemid 27200383)
33. Frumovitz M, Sun CC, Schover LR, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 2005;23:7428-36. (Pubitemid 46291804)
34. Greimel ER, Winter R, Kapp KS, et al. Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology 2009;18:476-82.
35. Distefano M, Riccardi S, Capelli G, et al. Quality of life and psychological distress in locally advanced cervical cancer patients administered pre-operative chemoradiotherapy. Gynecol Oncol 2008;111:144-50.